Enlivex Announces Issuance of European Patent Covering the Use of Allocetra to Prevent Cytokine Release Syndrome Resulting From CAR T-Cell Therapy
Enlivex Therapeutics Ltd. recently announced the issuance of a European patent, No. 3865189, titled Combination Immune Therapy and Cytokine Control Therapy for Cancer Treatment. The patent provides added intellectual property protection in Europe into at least 2037, with claims covering the use of for Allocetra for the prevention or amelioration of cytokine storms in cancer patients receiving CAR T-Cell therapy.
Allocetra is being developed as a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, Allocetra has the potential to provide a novel immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with leading therapeutic agents.
Enlivex is a clinical-stage macrophage reprogramming immunotherapy company developing Allocetra, a universal off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Resetting non-homeostatic macrophages into their homeostatic state is critical for immune system rebalancing and resolution of life-threatening conditions. For more information, visit http://www.enlivex.com.
Total Page Views: 776
